Table 1.

Status at the 1-year evaluation visit among patients with RA initiating a TNF inhibitor as their first ever biologic DMARD

	Etanercept	Infliximab	Adalimumab	Certolizumab	Golimumab	P

	N=1651	N-1366	N=1004	N-921	N=626

Observed percentage
On drug	70.6	66.4	69.2	65.2	68.0
EULAR good response*	28.0	23.9	25.9	24.3	27.8
DAS28 remission*	25.9	21.3	26.0	22.4	27.7
HAQ improvement*	28.0	24.5	29.0	25.0	24.8
28 Joint counts = 0*	23.3	16.8	20.4	19.0	21.6
Adjusted^† relative risk (95% CI)
On drug	Ref.	0.94 (0.89–1.00)	0.98 (0.92–1.04)	0.90 (0.84–0.96)	0.97 (0.90–1.04)	0.02
EULAR good response*	Ref.	0.82 (0.70–0.96)	0.95 (0.80–1.12)	0.84 (0.70–1.01)	0.96 (0.79–1.17)	0.10
DAS28 remission*	Ref.	0.83 (0.70–0.98)	1.02 (0.85–1.21)	0.89 (0.74–1.08)	1.00 (0.82–1.23)	0.12
HAQ Improvement*	Ref.	0.82 (0.70–0.96)	1.04 (0.89–1.21)	0.86 (0.73–1.03)	0.86 (0.71–1.05)	0.02
28 Joint count = 0*	Ref.	0.74 (0.61–0.89)	0.91 (0.75–1.11)	0.85 (0.69–1.04)	0.91 (0.73–1.13)	0.03

*LUNDEX corrected (1). ^†Sex, age, disease duration, RF, co-treatment (methotrexate, glucocorticoids.)